Literature DB >> 25610728

Transcriptional profiling of whole blood: a rich source of immune biomarkers in cancer.

Y Saenger1, E de Moll2, Y Fu1.   

Abstract

Immunotherapy is at the forefront of cancer treatment, and biomarkers are urgently needed to predict patient response to therapy. Recently, we discovered a 4-gene peripheral blood mRNA signature for prolonged survival in patients treated with tremelimumab. Peripheral blood mRNA is a readily accessible and under-utilized source of clinically relevant biomarkers.

Entities:  

Keywords:  biomarker; immunotherapy; mRNA; peripheral blood; tremelimumab

Year:  2014        PMID： 25610728      PMCID： PMC4292516          DOI： 10.4161/21624011.2014.944056

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  An immune-active tumor microenvironment favors clinical response to ipilimumab.

Authors:  Rui-Ru Ji; Scott D Chasalow; Lisu Wang; Omid Hamid; Henrik Schmidt; John Cogswell; Suresh Alaparthy; David Berman; Maria Jure-Kunkel; Nathan O Siemers; Jeffrey R Jackson; Vafa Shahabi
Journal:  Cancer Immunol Immunother       Date:  2011-12-07       Impact factor: 6.968

Review 2.  Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment.

Authors:  Thomas F Gajewski; Mercedes Fuertes; Robbert Spaapen; Yan Zheng; Justin Kline
Journal:  Curr Opin Immunol       Date:  2010-12-23       Impact factor: 7.486

3.  Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes.

Authors:  Shigehisa Kitano; Michael A Postow; Carly G K Ziegler; Deborah Kuk; Katherine S Panageas; Czrina Cortez; Teresa Rasalan; Mathew Adamow; Jianda Yuan; Philip Wong; Gregoire Altan-Bonnet; Jedd D Wolchok; Alexander M Lesokhin
Journal:  Cancer Immunol Res       Date:  2014-05-20       Impact factor: 11.151

4.  A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study.

Authors:  Robert W Ross; Matthew D Galsky; Howard I Scher; Jay Magidson; Karl Wassmann; Gwo-Shu Mary Lee; Leah Katz; Sumit K Subudhi; Aseem Anand; Martin Fleisher; Philip W Kantoff; William K Oh
Journal:  Lancet Oncol       Date:  2012-10-09       Impact factor: 41.316

5.  Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

Authors:  Antoni Ribas; Richard Kefford; Margaret A Marshall; Cornelis J A Punt; John B Haanen; Maribel Marmol; Claus Garbe; Helen Gogas; Jacob Schachter; Gerald Linette; Paul Lorigan; Kari L Kendra; Michele Maio; Uwe Trefzer; Michael Smylie; Grant A McArthur; Brigitte Dreno; Paul D Nathan; Jacek Mackiewicz; John M Kirkwood; Jesus Gomez-Navarro; Bo Huang; Dmitri Pavlov; Axel Hauschild
Journal:  J Clin Oncol       Date:  2013-01-07       Impact factor: 44.544

6.  Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma.

Authors:  John M Kirkwood; Paul Lorigan; Peter Hersey; Axel Hauschild; Caroline Robert; David McDermott; Margaret A Marshall; Jesus Gomez-Navarro; Jane Q Liang; Cecile A Bulanhagui
Journal:  Clin Cancer Res       Date:  2010-01-19       Impact factor: 12.531

7.  Blood mRNA expression profiling predicts survival in patients treated with tremelimumab.

Authors:  Yvonne Saenger; Jay Magidson; Bobby Liaw; Ellen de Moll; Sara Harcharik; Yichun Fu; Karl Wassmann; David Fisher; John Kirkwood; William K Oh; Philip Friedlander
Journal:  Clin Cancer Res       Date:  2014-04-10       Impact factor: 12.531

8.  Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients.

Authors:  Edward Cha; Mark Klinger; Yafei Hou; Craig Cummings; Antoni Ribas; Malek Faham; Lawrence Fong
Journal:  Sci Transl Med       Date:  2014-05-28       Impact factor: 17.956

9.  Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types.

Authors:  Paolo A Ascierto; Michael Kalos; David A Schaer; Margaret K Callahan; Jedd D Wolchok
Journal:  Clin Cancer Res       Date:  2013-03-01       Impact factor: 12.531

10.  Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab.

Authors:  Jianda Yuan; Jun Zhou; Zhiwan Dong; Sapna Tandon; Deborah Kuk; Katherine S Panageas; Philip Wong; Xinqi Wu; Jarushka Naidoo; David B Page; Jedd D Wolchok; F Stephen Hodi
Journal:  Cancer Immunol Res       Date:  2014-02       Impact factor: 11.151
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.